Celon Pharma SA (PL:CLN)
:CLN
Want to see PL:CLN full AI Analyst Report?
Top Page
Celon Pharma SA
(CLN)
Select Model
Select Model
Rating:51Neutral
Price Target:
zł22.50
▲(7.40% Upside)
Action:N/A
Date:09/14/25
Celon Pharma SA's overall stock score of 51 reflects a cautious outlook, driven primarily by mixed financial performance. Strengths include a stable balance sheet with low leverage, but significant weaknesses in profitability, declining revenue, and negative cash flows weigh heavily. Valuation concerns with a high P/E ratio of 73.28 further temper the score, while limited technical data provides little additional insight. Investors should focus on potential operational improvements.
Positive Factors
Strong Gross Profit Margin
A strong gross profit margin indicates effective cost management and pricing power, which can support long-term profitability as the company scales.
Negative Factors
Negative Revenue Growth
Negative revenue growth suggests challenges in maintaining sales momentum, which can hinder long-term business sustainability and market competitiveness.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Profit Margin
A strong gross profit margin indicates effective cost management and pricing power, which can support long-term profitability as the company scales.
Read all positive factors
Celon Pharma SA (CLN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
zł1.11B
Dividend Yield0.43%
Average Volume (3M)15.54K
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue GrowthN/A
EPS GrowthN/A
CountryPL
Employees562
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.48
Shares Outstanding53,856,500
10 Day Avg. Volume8,893
30 Day Avg. Volume15,545
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)3.02
Price to Sales (P/S)5.22
P/FCF Ratio-35.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.04
Revenue Forecast (FY)zł275.94M
Celon Pharma SA Business Overview & Revenue Model
Company Description
Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurologi...
How the Company Makes Money
Celon Pharma generates revenue primarily through the development and sale of its pharmaceutical products, as well as through strategic partnerships and collaborations with other biotechnology and pharmaceutical companies. Key revenue streams inclu...
Celon Pharma SA Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
75
Positive
Cash Flow
40
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 209.80M | 176.62M | 213.92M | 161.91M | 196.09M |
| Gross Profit | -39.48M | 113.45M | 147.10M | 95.45M | 134.37M |
| EBITDA | -10.48M | 14.96M | 32.71M | 9.32M | 27.81M |
| Net Income | -79.36M | -34.45M | -28.12M | -39.28M | -11.61M |
Balance Sheet | |||||
| Total Assets | 457.46M | 543.79M | 569.31M | 608.93M | 707.14M |
| Cash, Cash Equivalents and Short-Term Investments | 19.91M | 56.52M | 114.54M | 164.62M | 227.55M |
| Total Debt | 18.94M | 16.93M | 25.59M | 26.82M | 14.92M |
| Total Liabilities | 74.47M | 98.59M | 123.75M | 129.29M | 153.14M |
| Stockholders Equity | 363.25M | 445.21M | 445.56M | 479.65M | 554.00M |
Cash Flow | |||||
| Free Cash Flow | -30.57M | -34.13M | -41.13M | -38.61M | 2.60M |
| Operating Cash Flow | 23.86M | -11.34M | -8.31M | -4.70M | 43.95M |
| Investing Cash Flow | -21.64M | -7.49M | -21.64M | -31.47M | -121.05M |
| Financing Cash Flow | -9.76M | 13.32M | -20.59M | -28.72M | 180.91M |
Celon Pharma SA Technical Analysis
Negative
20.95
Price Trends
20.81
Negative
21.34
Negative
21.48
Negative
Market Momentum
-0.04
Positive
40.72
Neutral
26.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:CLN, the sentiment is Negative. The current price of 20.95 is below the 20-day moving average (MA) of 21.12, above the 50-day MA of 20.81, and below the 200-day MA of 21.48, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 40.72 is Neutral, neither overbought nor oversold. The STOCH value of 26.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PL:CLN.
Celon Pharma SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | zł119.92M | -1.80 | -59.73% | ― | -53.36% | -45.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | zł1.11B | -11.00 | ― | 0.43% | ― | ― | |
51 Neutral | zł611.24M | 26.99 | -1.25% | ― | 6.57% | ― | |
44 Neutral | zł523.67M | -8.91 | -110.42% | ― | -20.15% | 9.16% | |
42 Neutral | zł497.47M | -9.91 | -109.96% | ― | -70.55% | 4.43% |
* Healthcare Sector Average
PL:CLN
Celon Pharma SA
20.70
-2.95
-12.47%
PL:RVU
Ryvu Therapeutics SA
22.65
-10.00
-30.63%
PL:CTX
Captor Therapeutics SA
78.30
41.90
115.11%
PL:MOC
OncoArendi Therapeutics SA
5.34
-3.01
-36.05%
PL:SLV
Selvita SA
33.30
-1.50
-4.31%
PL:MAB
Mabion SA
7.42
-2.68
-26.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.